Home
Stampa
HomeStampa
HomeStampa
18:00 - 19:00 | Satellite Symposium
HIV and COVID-19: where we are and where we are going
19:00 - 20:30 | Lecture
ICAR 2023 Opening Session
19:00 - 20:30
ICAR 2023 Opening Session
20:30 - 22:30
ICAR 2023 Welcome Reception
15:00 - 17:30 | Pre-Conference advanced course
Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer
15:00 - 17:30 | Special Session
RaccontART Contest Awards: incontro con le scuole finaliste e premiazione
15:00 - 17:30 | Pre-Conference advanced course
Clinical virology: dealing with HIV infection today
15:00 - 17:30 | Pre-Conference advanced course
HIV infection in the migrant and refugee population
Satellite Symposium
HIV and COVID-19: where we are and where we are going
Con la sponsorizzazione non condizionante di: 
Satellite Symposium
HIV and COVID-19: where we are and where we are going
The life expectancy of people living with HIV (PLHIV) is now close to the one of HIV negative individuals. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), by providing new antiretroviral regimens providing high efficacy, genetic barrier, forgiveness, tolerability, and convenience. However, a 00virgolette00tailored00virgolette00 approach has to satisfy also needs and expectations of PLWH, in order to guarantee them a therapeutic success for long-term. The symposium is also aimed at providing new insights on SARS-CoV-2 infection, especially in high-risk populations, such as comorbid and immunocompromised individuals. Through an interactive talk, experts will discuss on challenges and current and future innovative strategies that can fill the unmet needs of people living with HIV and SARS-CoV-2, supporting individuals to overcome treatment barriers and improve their quality of life.
Chairs: G. Di Perri, C. Mussini
| Talk-show debate based on the following topics: | |
| 18.00 - 18.15 | What we need in HIV treatment today to achieve long term success?
S. Lo Caputo |
| 18.15 - 18.30 | What are the patients' needs in terms of adherence and forgiveness in HIV?
F. Maggiolo |
| 18.30 - 18.45 | COVID-19 and comorbidities. What challenges we need to face?
E. Nicastri |
| 18.45 - 19.00 | Discussion and final consideration |
Lecture
ICAR 2023 Opening Session
ICAR 2023 Opening Session
Chairs: G.V. Calvino, F. Ceccherini Silberstein, A. d'Arminio Monforte, M. Formisano, G. Ippolito, S. Lo Caputo, A. Saracino, F. Schloesser
| 19.00 - 19.20 | Introducing ICAR 2023. Chairs and Authorities' welcome addresses |
| RaccontART: the three Winners | |
| 19.20 - 20.20 | Keynote Lectures |
| 19.20 - 19.50 | Mauro Moroni Memorial Lecture: "Vaccine Hesitancy - A Story as Old as Vaccines Themselves"
C. Gainty |
| Chairs: Antonella d'Arminio Monforte (Milano), Giuseppe Ippolito (Roma) | |
| 19.20 - 19.50 | Mauro Moroni Memorial Lecture: "Vaccine Hesitancy - A Story as Old as Vaccines Themselves"
C. Gainty |
| 19.50 - 20.20 | Giulio Maria Corbelli Memorial Lecture: "Health pathways in transgender people. The denied rights of invisible people"
M. Formisano |
| Chairs: Giulia Valeria Calvino (Roma), Filippo Schloesser (Roma) | |
| 19.50 - 20.20 | Giulio Maria Corbelli Memorial Lecture: "Health pathways in transgender people. The denied rights of invisible people"
M. Formisano |
| 20.20 - 20.30 | Closing remarks |
ICAR 2023 Opening Session
ICAR 2023 Opening Session
Chairs: G.V. Calvino, F. Ceccherini Silberstein, A. d'Arminio Monforte, M. Formisano, G. Ippolito, S. Lo Caputo, A. Saracino, F. Schloesser
| 19.00 - 19.20 | Introducing ICAR 2023. Chairs and Authorities' welcome addresses |
| RaccontART: the three Winners | |
| 19.20 - 20.20 | Keynote Lectures |
| 19.20 - 19.50 | Mauro Moroni Memorial Lecture: "Vaccine Hesitancy - A Story as Old as Vaccines Themselves"
C. Gainty |
| Chairs: Antonella d'Arminio Monforte (Milano), Giuseppe Ippolito (Roma) | |
| 19.20 - 19.50 | Mauro Moroni Memorial Lecture: "Vaccine Hesitancy - A Story as Old as Vaccines Themselves"
C. Gainty |
| 19.50 - 20.20 | Giulio Maria Corbelli Memorial Lecture: "Health pathways in transgender people. The denied rights of invisible people"
M. Formisano |
| Chairs: Giulia Valeria Calvino (Roma), Filippo Schloesser (Roma) | |
| 19.50 - 20.20 | Giulio Maria Corbelli Memorial Lecture: "Health pathways in transgender people. The denied rights of invisible people"
M. Formisano |
| 20.20 - 20.30 | Closing remarks |
ICAR 2023 Welcome Reception
ICAR 2023 Welcome Reception
Pre-Conference advanced course
Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer
Pre-Conference advanced course
Current epidemiology and future perspectives on the prevention of STIs and HPV related anal cancer
Sexually Transmitted Infections (STIs) represent a concern for sexually active individuals. If undiagnosed, STIs can eventually cause serious complications. Immunization and pharmacological prophylaxis are emerging, as adjunct to periodic screening of asymptomatic people, as new strategies for approaching STIs in addition to treatment once the infection is established. A thorough overview of the current state of the art will be offered to participants. The dynamic of HPV transmission and the pathogenesis of this infection differs from the other STIs. The relevance of anal HPV infection and HPV related anal cancer among MSM and PLWH is emerging. The ANCHOR study represents a milestone in this field and its publication in June 2022 opened the way to the definition of the first screening guidelines for the prevention of this neoplasm, with particular attention to PLWH. A review of current literature on anal HPV infection and anal cancer risk among several key populations and a focus on these novel screening guidelines will be offered to participants.
Chairs: D. Calzavara, E.N. Cavallari
| 15.00 - 15.10 | Evaluation of participants' knowledge on the course topics through a live on-line questionnaire (APP)
D. Calzavara, E.N. Cavallari |
| 15.10 - 15.30 | New insights on vaccines to prevent STIs
D. Moschese |
| 15.30 - 15.50 | New insights on pharmacological approaches to prevent STIs
S. Venturelli |
| 15.50 - 16.15 | Discussion |
| 16.15 - 16.35 | HPV and anal cancer risk among MSM and PLWH
R.P. Iachetta |
| 16.35 - 16.55 | New screening guidelines for the prevention of HPV related anal cancer in MSM
M. Ridolfi |
| 16.55 - 17.20 | Discussion |
| 17.20 - 17.30 | Revaluation of participants' knowledge on the course topics through a live on-line questionnaire (APP)
D. Calzavara, E.N. Cavallari |
Special Session
RaccontART Contest Awards: incontro con le scuole finaliste e premiazione
Special Session
RaccontART Contest Awards: incontro con le scuole finaliste e premiazione
Giunto alla nona edizione e destinato agli studenti degli Istituti Scolastici Superiori, il Contest artistico RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV, Infezioni Sessualmente Trasmissibili e Covid-19. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. Al termine della Sessione, verranno premiati i primi tre classificati.
Chairs: F. Ceccherini Silberstein, M. Formisano, S. Lo Caputo, A. Saracino
| 15.00 - 15.15 | Benvenuto dei Presidenti ICAR 2023 |
| 15.15 - 15.30 | Introduzione e presentazione della Giuria Artistica e Tecnico-Scientifica
F. Ceccherini Silberstein, M. Errico |
| 15.30 - 17.00 | Presentazione delle Opere finaliste al Concorso a cura degli Istituti Scolastici
F. Ceccherini Silberstein, M. Errico |
| 17.00 - 17.15 | Premiazione primi 3 classificati |
| 17.15 - 17.30 | Conclusioni |
Pre-Conference advanced course
Clinical virology: dealing with HIV infection today
Pre-Conference advanced course
Clinical virology: dealing with HIV infection today
The scenario of HIV infection has dramatically changed in the last two decades. Since HIV became a treatable and "chronic disease", people living with HIV (PLHIV) require lifelong care and treatment. This is thanks to the progress of antiretroviral therapy (ART), which is increasingly effective, potent, tolerable and with a high genetic barrier. Concomitantly, the strategy for treating/preventing HIV infection has also changed over time: possibility of starting ART immediately upon diagnosis (test-and-treat), likely (virtually) increasing the chance of detect acute infection; opportunity to simplify the regimen in virosuppressed ART-experienced PLWH or prevent infection (pre-exposure prophylaxis, PrEP), using effective regimens with just two active components and/or based on long-acting injectable formulation. Both oral and injectable PREP have been shown to greatly reduce the risk (incidence) of HIV infection. In both ART-naive and -experienced PLWH, these strategies can promote retention in care, treatment adherence and drug tolerability, ultimately improving the overall quality of life of PLWH. Despite increasing evidence of the efficacy, safety and tolerability of these new strategies in both ART-naive and -experienced PLWH, it is mandatory to evaluate them in clinical practice settings. In this regard, it is crucial to strictly monitor and follow PLWH from the time of diagnosis, via: I) standard surrogate markers (CD4 and HIV-RNA); II) markers of inflammation/immune-activation panels; III) total HIV-DNA, as a marker of the reservoir; and IV) genotypic tests for detecting primary and secondary drug resistance. To date, microfluidic technologies (microfluidic ELISA, digital droplet PCR and "next generation sequencing), which have enhanced laboratory performances (higher sensitivity, higher throughput) could fulfil the needs of a routine practice in clinical virology improving, in turn, the management of "present-day" ART-naive and virologically suppressed PLWH.
Chairs: G. Lapadula, F. Lombardi
| 15.00 - 15.30 | Proviral DNA/transcription-competent reservoir as a marker for monitoring the efficacy of novel antiretroviral strategies (simplification/LA) in virosuppressed PLWH:
- clinical implication/interpretation of the results
F. Saladini |
| 15.30 - 16.00 | Diagnosis and Management of Acute HIV:
- Diagnostic algorithm
- Clinical relevance of early detection
V. Micheli |
| 16.00 - 16.30 | NGS in HIV: present and future challenges:
- Understand the cut-off for detection of the minority variants (clinical interpretation)
- Whole genome sequencing (WGS) in the light of new strategies based on antiretrovirals acting on several different targets
D. Armenia |
| 16.30 - 17.00 | A new paradigm for antiretroviral delivery: long-acting new antivirals and strategies for the treatment and prevention of HIV:
- Clinical and virological perspectives
R. Rossotti |
| 17.00 - 17.30 | Discussion |
Pre-Conference advanced course
HIV infection in the migrant and refugee population
Pre-Conference advanced course
HIV infection in the migrant and refugee population
There were around 281 million international migrants in the world in 2021, which equates to 3.6 per cent of the global population. Migrant populations are more likely to suffer from poor health in general and HIV infection in particular. This is due to the epidemiological burden in the country of origin, as well as the vulnerability conditions during travel and the poor living conditions once in Europe, which expose them to every vulnerability. In addition, as with other people living with HIV/AIDS, migrants who are HIV-positive are subject to stigmatization and discrimination, and therefore, they hide their HIV status as long as possible, thus making support services unavailable to them. Most migrant populations live in a legal vacuum, with no stay or work permit in the host country, making frequently this an element of non-access to health services. The aim of this course is to deepen our understanding of the migration phenomenon and HIV pathology by highlighting epidemiological data, good practises of public and private entities, sharing difficulties, and approaching the problem with possible, applicable, and sustainable solutions.
Chairs: A. Caraglia, M. Cascio, T.S. Prestileo
Discussants: F. Di Gennaro, L.A.R. Rancilio, C. Torti
| 15.00 - 15.20 | Migrant and refugees in Italy: current scenarios
D.P. Betti |
| 15.20 - 15.40 | HIV infection in migrant population - Learning from each other
C. Torti |
| 15.40 - 16.00 | NGOs as a first response for migrant integration and approach to the health system
L.A.R. Rancilio |
| 16.00 - 16.20 | Public health engagement of migrants: the role of Hospital and University
F. Di Gennaro |
| 16.20 - 17.30 | Round table |
09:00 - 10:00 | Session
Keynote Lectures
10:05 - 11:05 | Symposium
Controversies in HIV clinical virology
11:10 - 12:10 | Sponsored Symposium
HIV treatment outcomes with DTG/3TC in Naive and Experienced PLHIV
12:15 - 13:15 | Symposium
The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONs
13:20 - 14:20 | Oral Communications
Clinical issues blinking to laboratory
14:30 - 15:30 | Sponsored Symposium
B/F/TAF: your trusted partner also in apparently un-complicated patients
15:35 - 16:35 | Symposium
New issues on antiretroviral drug optimization
16:40 - 18:00 | Symposium
How to manage Heavily Treatment-Experienced patients (HTE)
10:05 - 11:05 | Sponsored Symposium
Do mAbs still play a role in the early treatment of COVID-19 patients?
11:10 - 12:10 | Satellite Symposium
A new era of HDV treatment: relevance of HDV control in coinfected patients
12:15 - 13:15 | Oral Communications
Outcome in first-line regimens
13:20 - 14:20 | Oral Communications
Viral infections old and new
14:30 - 15:30 | Oral Communications
Antiviral treatment in COVID-19
15:35 - 16:35 | Satellite Symposium
From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy
16:40 - 17:40 | Symposium
Immunotherapies in chronic viral infections: what will the future bring?
10:05 - 11:05 | Expert Meeting
Individualization and evolution of HIV management with the next generation of NNRTI: the future is now
11:10 - 12:10 | Oral Communications
Immune response in SARS-CoV-2
12:15 - 13:15 | Expert Meeting
Every left is lost, let's vaccinate
13:20 - 14:20 | Oral Communications
Preferences limitations and long term outcomes
14:30 - 15:30 | Expert Meeting
Long-acting antimicrobial experiences in real world patients: toward paradigm changement?
15:35 - 16:35 | Oral Communications
Severe clinical issues in HIV-1 infection
16:40 - 17:50 | Oral Communications
The increasing burden of STIs
10:05 - 11:05 | Oral Communications
Emerging immunological and virological concepts in viral hepatitis
11:10 - 12:10 | Oral Communications
Inflammation: a major pathogenetic process
12:15 - 13:15 | Oral Communications
One size does not fit all
13:20 - 14:20 | Oral Communications
Immune response to viruses
14:30 - 15:30 | Oral Communications
HIV: much left to do
15:35 - 16:35 | Oral Communications
Oral or injectable 2-drug regimens
16:40 - 17:50 | Oral Communications
Vaccine in frail patients
10:05 - 11:05 | Oral Communications
Epidemiology trends in infections
12:15 - 13:15 | Oral Communications
Early treatment for COVID-19
13:20 - 14:20 | Oral Communications
COVID-19 outcome in special population
14:30 - 15:30 | Oral Communications
Cardiovascular and malignancies
15:35 - 16:35 | Oral Communications
Prevention, access and engagement
16:40 - 17:40 | Oral Communications
Clinical outcome of SARS-CoV-2 infection
11:10 - 12:10 | Special Session
Health and prevention in transgender people
12:15 - 13:15 | Parallel Session
ARCA Scientific Board
15:35 - 16:35 | Special Session
The Italian Fast-track Cities: strengths and weaknesses of a growing movement
Session
Keynote Lectures
Session
Keynote Lectures
Chairs: G. Antonelli, F. Castelli, A. Gori
| 09.00 - 09.30 | All you always wanted to know about clinical pharmacology but were afraid to ask
S. Bonora |
| 09.30 - 10.00 | Simplifying a complex issue: how to tailor drug resistance into clinical practice
A.M. Geretti |
Symposium
Controversies in HIV clinical virology
Symposium
Controversies in HIV clinical virology
While modern antiretroviral therapy has been progressing towards increased potency, convenience and durability, controversies in HIV virology and pharmacology remain. This symposium focuses on two specific issues, namely HIV drug resistance and low-level viremia, through an attractive clinician vs. virologist format. The incidence of HIV drug resistance has been decreasing due to expanded use of high genetic barrier drugs and lower rates of virological failure. However, a proportion of PLWH still develop or harbour drug resistance patterns which can challenge treatment options. In addition, people with controlled viremia can benefit from HIV DNA drug resistance testing and the advent of high-resolution sequencing methods have recently added a new layer of opportunities and challenges. On the other hand, how to deal with low-level viremia remains an open debate requiring an integrated view on antiretroviral pharmacology, adherence and the risk of emergent resistance.
Chairs: A. Callegaro, A. Lazzarin
| 10.05 - 10.35 | Round Table: Should we still care about drug resistance?
The clinician's and virologist's view
V. Micheli, S. Rusconi |
| 10.35 - 11.05 | Round Table: How to deal with low-level viraemia.
Clinician and biologist in comparison
F. Lombardi, F. Maggiolo |
Sponsored Symposium
HIV treatment outcomes with DTG/3TC in Naive and Experienced PLHIV
Symposium
The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONs
Symposium
The case of weight gain: is it a relevant issue in the management of PWH? PROs and CONs
Weight gain in people on antiretroviral treatment has been observed in numerous cohorts and continues to be an issue of intense debate. Indeed, several aspects are not yet clear: how weight gain is affected by specific antiretroviral treatments, pre-existing body weight or other factors, what are the underlying mechanisms, and to what extent is this a clinically relevant issue, depending on actual rate and extent and associations with metabolic disorders and other conditions. This symposium aims to weight pros and cons from ID and other specialists on whether weight gain is clinically relevant in PWH and gain knowledge towards optimal management.
Chairs: P. Bonfanti, F. Vichi
| 12.15 - 12.20 | Introduction
G. Madeddu |
| 12.20 - 12.30 | YES, weight gain is a truly relevant issue
P. Maggi |
| 12.30 - 12.40 | NO, weight gain is not that much relevant afterall
S. Cicalini |
| 12.40 - 12.50 | The association of weight gain with (diabetes and) metabolic alterations: an endocrinological view
D. Gianfrilli |
| 12.50 - 13.00 | Increased CV risk related to minimal to substantial weight gain: a cardiovascolar view
G. d'Ettorre |
| 13.00 - 13.15 | Round Table and conclusion
P.M. Cinque, F. Vichi |
Oral Communications
Clinical issues blinking to laboratory
Oral Communications
Oral Communications: Clinical issues blinking to laboratory
Chairs: S. Cicalini, C. Gervasoni
| 13.20 - 13.25 | Introduction
S. Cicalini, C. Gervasoni |
| 13.25 - 13.35 | ID 465 This goes out to the underdog: how not to neglect sexually transmitted infections
|
| 13.37 - 13.47 | ID 25 The case of dolutegravir plus darunavir antiretroviral regimens: Is it always useful to double the drug doses?
|
| 13.49 - 13.59 | ID
|
| 14.01 - 14.11 | ID 306 Durability and effectiveness of dual versus triple INSTI-based antiretroviral therapy in a real-world cohort in Palermo
|
| 14.13 - 14.20 | Conclusion
S. Cicalini, C. Gervasoni |
Sponsored Symposium
B/F/TAF: your trusted partner also in apparently un-complicated patients
Simposio promozionale di:
Sponsored Symposium
B/F/TAF: your trusted partner also in apparently un-complicated patients
Gilead, a historical company involved in advancing HIV therapy, will host a promotional symposium called "B/F/TAF: Your trusted partner also in apparently uncomplicated patients." The symposium will focus on apparently uncomplicated patients in order to better understand their characteristics and raise awareness of the complexity of HIV. Through an analysis of patients' clinical needs, the often-overlooked CNS adverse events, the importance of long-term safety in therapy, and the need to control viral replication for as long as possible, we will draw on the experience of B/F/TAF to present key data on long-term safety and maximal and durable viral suppression, with the aim of identifying the optimal treatment choices for these patients.
Chair: G.C. Marchetti
| 14.30 - 14.35 | Introduction
G.C. Marchetti |
| 14.35 - 14.45 | Gilead's commitment in HIV
F. da Silva |
| 14.45 - 15.05 | Maximal and durable viral suppression in apparently un-complicated HIV Patients: The role of B/F/TAF
S. Bonora |
| 15.05 - 15.25 | The confidence of B/F/TAF Long-Term Safety in HIV Treatment
G. Madeddu |
| 15.25 - 15.30 | Q&A
G.C. Marchetti |
Symposium
New issues on antiretroviral drug optimization
Symposium
New issues on antiretroviral drug optimization
With currently available antiretroviral therapy, most people with HIV infection can achieve and maintain HIV viral suppression. Advances in antiretroviral treatment and a better understanding of drug resistance have made it possible to consider switching a person with HIV from an effective regimen to another in defined circumstances. New burning topics including the significance of the archived and resistant HIV, will be discussed
Chairs: S. Di Giambenedetto, G. Rizzardini
| 15.35 - 15.50 | Role and impact of drug-resistant and archived HIV
M. Zazzi |
| 15.50 - 16.05 | How much adherence is necessary to avoid drug-resistance with modern ART 2DRs and 3DRs?
A. Di Biagio |
| 16.05 - 16.20 | Pharmacological interactions: ART and the rest of world
A. Calcagno |
| 16.20 - 16.35 | Discussion |
Symposium
How to manage Heavily Treatment-Experienced patients (HTE)
Con la sponsorizzazione non condizionante di: 
Symposium
How to manage Heavily Treatment-Experienced patients (HTE)
HTE patients are described as those having two or less antiretroviral (ARV) classes available for use with limited fully active ARV agents within each class. A detailed understanding of the underlying processes that caused previous treatment failures, diagnostics to define resistance, resistance mechanisms and ARV pharmacology should all function in tandem to determine the next steps of clinical care. This Symposium provides an overview of the clinical approach to care, including diagnostics, regimen creation and a broad array of both currently available and upcoming ARVs that may be used in regimens for HTE patients.
Chairs: M. Galli, F. Maggiolo, M. Santoro
Moderators: F. Maggiolo, M. Santoro
Discussants: A. Castagna, A. Di Biagio, S. Lo Caputo, S. Rusconi
| 16.40 - 16.55 | Who are the HTE patients?
S. Lo Caputo |
| New classes of antiretroviral drugs with novel mechanisms of action: | |
| 16.55 - 17.10 | Fostemsavir, the HIV-1 attachment inhibitor
S. Rusconi |
| 17.10 - 17.25 | Lenacapavir, the inhibitor of HIV capsid function
A. Di Biagio |
| 17.25 - 17.40 | U=U in HTE patients: myth or reality?
A. Castagna |
| 17.40 - 18.00 | Q&A and Panel Discussion |
Sponsored Symposium
Do mAbs still play a role in the early treatment of COVID-19 patients?
Satellite Symposium
A new era of HDV treatment: relevance of HDV control in coinfected patients
Con la sponsorizzazione non condizionante di:
Satellite Symposium
A new era of HDV treatment: relevance of HDV control in coinfected patients
Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5-10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15-25 million people. Hepatitis delta is the most severe of all chronic viral hepatitis, leading to cirrhosis, liver cancer and/or transplantation in most patients. The only treatment available until recently was peginterferon alfa, with poor results and significant side effects. The recent approval of bulevirtide, a lipopeptide that blocks HBV/HDV entry, has revolutionized the field. Given that sexual and parenteral transmission routes are the most frequent for the acquisition of HBV and HDV, shared with HIV infection and HBV/HDV and HIV coinfection. The clinical outcome of hepatitis delta is worst in the HIV setting, with more frequent liver complications.
Chairs: A. d'Arminio Monforte, T.A. Santantonio
| 11.10 - 11.30 | New therapeutic options for HDV: from RCT to Real world
E. Degasperi |
| 11.30 - 11.50 | HIV-HBV-HDV coinfected patients in ICONA Cohort: practical management recommendations
M. Puoti |
| 11.50 - 12.00 | Discussion |
| 12.00 - 12.10 | The patient voice
C. Taibi |
Oral Communications
Outcome in first-line regimens
Oral Communications
Oral Communications: Outcome in first-line regimens
Chairs: S.M. Ferrara, N. Gianotti
| 12.15 - 12.20 | Introduction
S.M. Ferrara, N. Gianotti |
| 12.20 - 12.30 | ID 250 ReTe AIDS: shared telephone counselling strategies to meet people's information needs on STIs
|
| 12.32 - 12.42 | ID 313 Doxycycline post-exposure prophylaxis (DoxyPEP) real-life effectiveness in a cohort of men who have sex with men in Milan, Italy
|
| 12.44 - 12.54 | ID 280 CNS relapse risk in HIV-positive patients affected by DLBCL and HGBL - a retrospective study of the MUSTHAL cohort
|
| 12.56 - 13.06 | ID 38 SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43
|
| 13.08 - 13.15 | Conclusion
S.M. Ferrara, N. Gianotti |
Oral Communications
Viral infections old and new
Oral Communications
Oral Communications: Viral infections old and new
Chairs: V. Micheli, L. Sarmati
| 13.20 - 13.25 | Introduction
V. Micheli, L. Sarmati |
| 13.25 - 13.35 | ID 373 Varicella Zoster Virus Vaccination in immunocompromised patients with haematological and rheumatological diseases: specific T-cell response measured with an in-house Interferon Gamma Release Assay
|
| 13.37 - 13.47 | ID
|
| 13.49 - 13.59 | ID 288 Prevalence of sexually transmitted infections in cisgender women coming to walk-in Center
|
| 14.01 - 14.11 | ID 52 Two years analysis of COBATEST data in Ancona Checkpoint and our experience of “tele visita PrEP”
|
| 14.13 - 14.20 | Conclusion
V. Micheli, L. Sarmati |
Oral Communications
Antiviral treatment in COVID-19
Oral Communications
Oral Communications: Antiviral treatment in COVID-19
Chairs: A. Franco, M. Lichtner
| 14.30 - 14.35 | Introduction
A. Franco, M. Lichtner |
| 14.35 - 14.45 | ID 346 New tools in the management of innovative HIV therapy. Pilot study
|
| 14.47 - 14.57 | ID 188 Real-life impact of doravirin-based regimens on LDL cholesterol value
|
| 14.59 - 15.09 | ID 233 Insights into patients perspectives: identifying barriers in the transition from oral to injectable antiretroviral treatment
|
| 15.11 - 15.21 | ID
|
| 15.23 - 15.30 | Conclusion
A. Franco, M. Lichtner |
Satellite Symposium
From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy
Satellite Symposium
From prevention to cure in SARS-CoV-2: bivalent vaccines and antiviral therapy
COVID-19 places tremendous burden to public health and economy system. The roll-out of COVID-19 vaccines at the beginning of 2021 marked a key turning point in the fight against the global pandemic by limiting disease transmission and progression to death, albeit variable vaccination coverage. Early antiviral treatments can help reduce the risk of serious illness especially in adults at high risk of progressing to severe COVID-19 (as immunocompromised individuals) and may continue to shed virus and remain symptomatic for a longer period.
Chairs: A. Cingolani, R. Parrella
| 15.35 - 15.50 | SARS-CoV-2 early antiviral treatment: in which patients?
M. Andreoni |
| 15.50 - 16.05 | Antiviral therapy in COVID-19 patients
A. Antinori |
| 16.05 - 16.15 | Discussion |
| 16.15 - 16.30 | SARS-CoV-2 bivalent vaccines efficacy in today's epidemiological scenario
P.L. Lopalco |
| 16.30 - 16.35 | Discussion |
Symposium
Immunotherapies in chronic viral infections: what will the future bring?
Symposium
Immunotherapies in chronic viral infections: what will the future bring?
Immunotherapies, already well established in the management of cancer, are emerging as important tools in the control of chronic viral infections. There are challenges: we need to understand whether stimulating a sluggish immune response, tackling immune inhibition, or directly transferring immune mediators is the best approach; we must carefully consider potential safety liabilities; and we wish for improved biomarkers to optimise patient stratification and monitoring. We will discuss two different scenarios that pose different risk/benefit considerations but are equally challenging. Firstly, we will talk about the initial hopes, subsequent disappointments and current promising approaches that bring us closer to curing chronic HBV infection. A brief case history will then highlight the problem of CMV infection unresponsive to traditional interventions in the setting of immunodeficiency, followed by a lecture on how transfer of CMV-specific T-cells can restore protective antiviral immunity in transplant recipients patients. Come along to this exciting symposium to hear how cutting-edge science is being translated into clinical practice!
Chairs: N. Coppola, V. Svicher
Discussants: P.E. Comoli, N. Coppola, P. Fisicaro, A.M. Geretti, M. Lichtner, V. Svicher
| 16.40 - 17.00 | Immunotherapies to cure chronic HBV infection
P. Fisicaro |
| 17.00 - 17.05 | Case history: The challenge of unresponsive CMV infection
M. Lichtner |
| 17.05 - 17.25 | Adoptive immunotherapies for CMV and other viruses in the transplant setting
P.E. Comoli |
| 17.25 - 17.40 | Q&A and Panel Discussion |
Expert Meeting
Individualization and evolution of HIV management with the next generation of NNRTI: the future is now
Oral Communications
Immune response in SARS-CoV-2
Oral Communications
Oral Communications: Immune response in SARS-CoV-2
Chairs: M. Biasin, C. Tincati
| 11.10 - 11.15 | Introduction
M. Biasin, C. Tincati |
| 11.15 - 11.25 | ID 290 Hepatitis A virus protection status in cis males and transgender females who live with HIV and have sex with men: a retrospective observational study
|
| 11.27 - 11.37 | ID 395 Clinical and Epidemiological Insights in Severe Influenza patients admitted to emergency department with respiratory symptoms in the fourth year of SARS-CoV-2 pandemic
|
| 11.39 - 11.49 | ID 100 Understanding and managing new HIV diagnoses in members of “generation Z” (1996-2010) in Milan, Italy: project GenZ HIV-support
|
| 11.51 - 12.01 | ID 143 Fatty liver disease in a non-HBV and non-HCV coinfected cohort of PLWH in Southern Italy: a preliminary observational analysis
|
| 12.03 - 12.10 | Conclusion
M. Biasin, C. Tincati |
Expert Meeting
Every left is lost, let's vaccinate
Oral Communications
Preferences limitations and long term outcomes
Oral Communications
Oral Communications: Preferences limitations and long term outcomes
Chairs: A. Cascio, E. Girardi
| 13.20 - 13.25 | Introduction
A. Cascio, E. Girardi |
| 13.25 - 13.35 | ID 189 “Serological positivity of Treponema pallidum in tertial Rome hospital: a retrospective epidemiological study in last five years (2019-2023)”
|
| 13.37 - 13.47 | ID 273 Burden of advanced HIV disease (AHD) among antiretroviral therapy (ART)-experienced persons with HIV (PWH) in Italy over the past 20 years
|
| 13.49 - 13.59 | ID 462 Case report on the effect of antiretroviral treatment on a young man with uncertain HIV diagnosis, immune dysfunction and high expression of HERVs
|
| 14.01 - 14.11 | ID
|
| 14.13 - 14.20 | Conclusion
A. Cascio, E. Girardi |
Expert Meeting
Long-acting antimicrobial experiences in real world patients: toward paradigm changement?
Oral Communications
Severe clinical issues in HIV-1 infection
Oral Communications
Oral Communications: Severe clinical issues in HIV-1 infection
Chairs: A. Cozzi-Lepri, M. De Gennaro
| 15.35 - 15.40 | Introduction
A. Cozzi-Lepri, M. De Gennaro |
| 15.40 - 15.50 | ID 470 CD8 encephalitis HIV-related in a naive patient
|
| 15.52 - 16.02 | ID 175 Bulevirtide for the treatment of hepatitis D: a case series
|
| 16.04 - 16.14 | ID 113 Nontuberculous mycobacteria pulmonary infection and risk factors: a case series
|
| 16.16 - 16.26 | ID 355 The impact of pharmacogenetics on long-acting cabotegravir and rilpivirine plasma exposures in the clinical setting
|
| 16.28 - 16.35 | Conclusion
A. Cozzi-Lepri, M. De Gennaro |
Oral Communications
The increasing burden of STIs
Oral Communications
Oral Communications: The increasing burden of STIs
Chairs: S. Cecere, B. Suligoi
| 16.40 - 16.45 | Introduction
S. Cecere, B. Suligoi |
| 16.45 - 16.55 | ID 396 Preliminary real world experience in a cohort of PLWH undergoing LA CAB/RPV in Latina: a heterogeneous population with homogeneous efficacy and satisfaction
|
| 16.57 - 17.07 | ID 345 Factors associated with PrEP start after nPEP conclusion. A retrospective analysis
|
| 17.09 - 17.19 | ID 474 A case of syphilitic vitritis with complicated course
|
| 17.21 - 17.31 | ID 392 Prevalence and correlates of Hepatic Steatosis and Metabolic-associated Fatty Liver Disease in a cohort of People Living With HIV
|
| 17.33 - 17.43 | ID 445 Successful re-treatment after two relapses with 24-week sofosbuvir/velpatasvir and ribavirin in a patient with chronic genotype 3 HCV infection, HIV, and end stage renal disease
|
| 17.45 - 17.50 | Conclusion
S. Cecere, B. Suligoi |
Oral Communications
Emerging immunological and virological concepts in viral hepatitis
Oral Communications
Oral Communications: Emerging immunological and virological concepts in viral hepatitis
Chairs: N. Coppola, V. Svicher
| 10.05 - 10.10 | Introduction
N. Coppola, V. Svicher |
| 10.10 - 10.20 | ID 62 VILLA MARAINI FOUNDATION: MEET PEOPLE TO KILL INFECTION
|
| 10.22 - 10.32 | ID 340 The evolution of Monkeypox virus: a genetic and structural analysis of mutations in proteins involved in host-pathogen interaction
|
| 10.34 - 10.44 | ID 164 Parvovirus B19 infection in a woman affected by psoriasis, a case report
|
| 10.46 - 10.56 | ID 177 Network analysis of proviral DNA mutations in People with 4-class-resistant HIV-1: Data from the PRESTIGIO Registry
|
| 10.58 - 11.05 | Conclusion
N. Coppola, V. Svicher |
Oral Communications
Inflammation: a major pathogenetic process
Oral Communications
Oral Communications: Inflammation: a major pathogenetic process
Chairs: A. De Maria, D.L. Trabattoni
| 11.10 - 11.15 | Introduction
A. De Maria, D. Trabattoni |
| 11.15 - 11.25 | ID
|
| 11.27 - 11.37 | ID
|
| 11.39 - 11.49 | ID 266 Prolonged combination treatment: an efficient and safe strategy for managing SARS-CoV-2 infection in immunocompromised patients
|
| 11.51 - 12.01 | ID 372 Multidrug resistant bacteria (MDRB) and bed turnover: is it true that the fragile patient should be moved the least possible?
|
| 12.03 - 12.10 | Conclusion
A. De Maria, D. Trabattoni |
Oral Communications
One size does not fit all
Oral Communications
Oral Communications: One size does not fit all
Chairs: S. Babudieri, I. Pennini
| 12.15 - 12.20 | Introduction
S. Babudieri, I. Pennini |
| 12.20 - 12.30 | ID 339 Carotid intima media thickness (IMT) and statins prescriptions in the real life setting of the Archi Prevaleat cohort
|
| 12.32 - 12.42 | ID 265 Cognitive Performance in Older People with and without HIV in the GEPPO Cohort
|
| 12.44 - 12.54 | ID 199 Metabolic and weight changes in people with HIV after switching to long-acting therapy with cabotegravir and rilpivirine: results from the SCohoLART study
|
| 12.56 - 13.06 | ID
|
| 13.08 - 13.15 | Conclusion
S. Babudieri, I. Pennini |
Oral Communications
Immune response to viruses
Oral Communications
Oral Communications: Immune response to viruses
Chairs: C. Agrati, I. Vicenti
| 13.20 - 13.25 | Introduction
C. Agrati, I. Vicenti |
| 13.25 - 13.35 | ID 253 Bulevirtide effectiveness and safety in cirrhotic and non cirrhotic patients in Sardinia
|
| 13.37 - 13.47 | ID 56 Adherence to HIV infection care at IRCCS San Raffaele Hospital: current status and Re-stART project
|
| 13.49 - 13.59 | ID 316 Chemsex knowledge and use among PrEP-users and PWH: a survey on the Milanese scene
|
| 14.01 - 14.11 | ID 258 Rapid ART initiation and Retention in care of people living with HIV: a six-years observational study in foreigners versus Italian-borne
|
| 14.13 - 14.20 | Conclusion
C. Agrati, I. Vicenti |
Oral Communications
HIV: much left to do
Oral Communications
Oral Communications: HIV: much left to do
Chairs: M. Farinella, S. Mattioli
| 14.30 - 14.35 | Introduction
M. Farinella, S. Mattioli |
| 14.35 - 14.45 | ID 140 The effect of long-acting therapy on perceived stigma in people living with HIV: preliminary data
|
| 14.47 - 14.57 | ID 441 Information and Misinformation on HIV and the Narration of the Evidence U=U: a mixed method analysis on social media in Italy
|
| 14.59 - 15.09 | ID
|
| 15.11 - 15.21 | ID 105 Antibody and Interferon response in HIV patients following mRNA-based SARS-CoV-2 vaccine
|
| 15.23 - 15.30 | Conclusion
M. Farinella, S. Mattioli |
Oral Communications
Oral or injectable 2-drug regimens
Oral Communications
Oral Communications: Oral or injectable 2-drug regimens
Chairs: V. Esposito, A. Tavelli
| 15.35 - 15.40 | Introduction
V. Esposito, A. Tavelli |
| 15.40 - 15.50 | ID 399 Is CAB/RPV-LA able to modulate residual immune activation in people living with HIV? A pilot single-arm longitudinal study
|
| 15.52 - 16.02 | ID 440 Specific T-cell responses to Varicella Zoster Virus glycoprotein E one year after vaccination with a recombinant adjuvanted subunit vaccine in people with multiple sclerosis on disease modifying treatments
|
| 16.04 - 16.14 | ID 391 HIV screening and treatment in two penitentiaries in Northern Italy: a retrospective analysis
|
| 16.16 - 16.26 | ID
|
| 16.28 - 16.35 | Conclusion
V. Esposito, A. Tavelli |
Oral Communications
Vaccine in frail patients
Oral Communications
Oral Communications: Vaccine in frail patients
Chairs: S. Antinori, S. Nozza
| 16.40 - 16.45 | Introduction
S. Antinori, S. Nozza |
| 16.45 - 16.55 | ID 83 Estimating the potential health economic value of universal opt-out HIV testing in emergency departments in Italy: A modelling study
|
| 16.57 - 17.07 | ID 170 Treatment for hepatitis C in prison: diagnostic and therapeutic gaps in migrants
|
| 17.09 - 17.19 | ID 248 The evolving landscape of COVID-19: Characteristics and factors associated with disease severity and mortality in recent hospitalisations
|
| 17.21 - 17.31 | ID 252 Evaluating tolerance and safety profiles of Pre-Exposure Prophylaxis (PrEP) for HIV: insights from renal and hepatic function monitoring
|
| 17.33 - 17.43 | ID 263 High lipid levels in patients living with HIV undergoing triple antiretroviral therapy
|
| 17.45 - 17.50 | Conclusion
S. Antinori, S. Nozza |
Oral Communications
Epidemiology trends in infections
Oral Communications
Oral Communications: Epidemiology trends in infections
Chairs: E. Girardi, B. Marchini
| 10.05 - 10.10 | Introduction
E. Girardi, B. Marchini |
| 10.10 - 10.20 | ID 54 Long Acting Cabotegravir and Rilpivirine plasma and intracellular pharmacokinetics in the Clinical Setting
|
| 10.22 - 10.32 | ID 284 Kidney transplantation in people living with HIV: ten-year experience in Modena
|
| 10.34 - 10.44 | ID 108 Cases of untyped Influenza A virus in northern Italy
|
| 10.46 - 10.56 | ID 437 Incidence of transmitted drug resistance mutations among newly diagnosed HIV‐1 patients: a 6-month retrospective analysis
|
| 10.58 - 11.05 | Conclusion
E. Girardi, B. Marchini |
Oral Communications
Early treatment for COVID-19
Oral Communications
Oral Communications: Early treatment for COVID-19
Chairs: E. Nicastri, M. Tavio
| 12.15 - 12.20 | Introduction
E. Nicastri, M. Tavio |
| 12.20 - 12.30 | ID
|
| 12.32 - 12.42 | ID 311 Experienced PWH switching to 3TC/TDF/DOR in outpatient setting: real-life data on Lipid changes and ASCVD risk from an Italian multicenter cohort
|
| 12.44 - 12.54 | ID 420 Clinical features and impact on mortality of COVID-19 epidemics in patients with Non-Hodgkin lymphoma: long-term results from a tertiary center in Italy
|
| 12.56 - 13.06 | ID
|
| 13.08 - 13.15 | Conclusion
E. Nicastri, M. Tavio |
Oral Communications
COVID-19 outcome in special population
Oral Communications
Oral Communications: COVID-19 outcome in special population
Chairs: G.B. Buccoliero, R. Rossotti
| 13.20 - 13.25 | Introduction
G.B. Buccoliero, R. Rossotti |
| 13.25 - 13.35 | ID 171 Monitoring quality of life in PLWH using a patient reported outcomes (PRO) and screening tools for emotional and cognitive vulnerability
|
| 13.37 - 13.47 | ID 477 20-year review of neurological outcomes in HIV-exposed uninfected children in a pediatric HIV referral center
|
| 13.49 - 13.59 | ID
|
| 14.01 - 14.11 | ID 148 Exploring effectiveness and tolerance: switching to long-acting cabotegravir plus rilpivirine therapy in virologically suppressed individuals with HIV
|
| 14.13 - 14.20 | Conclusion
G.B. Buccoliero, R. Rossotti |
Oral Communications
Cardiovascular and malignancies
Oral Communications
Oral Communications: Cardiovascular and malignancies
Chairs: F. Mazzotta, M.E. Quiros Roldan
| 14.30 - 14.35 | Introduction
F. Mazzotta, M.E. Quiros Roldan |
| 14.35 - 14.45 | ID 460 Syphilis among PLWH: prevalence of the infection in relation to COVID-19 outbreak
|
| 14.47 - 14.57 | ID
|
| 14.59 - 15.09 | ID 208 Back to the measles – first evidence of viral circulation in Liguria, Northern Italy, 2024
|
| 15.11 - 15.21 | ID 46 ONGOING PSYCHO-SOCIAL INTERVENTIONS: PRELIMINARY DATA OF THE “FRAGIL/mente” PROJECT
|
| 15.23 - 15.30 | Conclusion
F. Mazzotta, M.E. Quiros Roldan |
Oral Communications
Prevention, access and engagement
Oral Communications
Oral Communications: Prevention, access and engagement
Chairs: M.L. Cosmaro, E. Girardi
| 15.35 - 15.40 | Introduction
M.L. Cosmaro, E. Girardi |
| 15.40 - 15.50 | ID 331 Beyond the barriers: the impact of HPV vaccination program variation among MSM PLWH
|
| 15.52 - 16.02 | ID 75 Real-world data on the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH): 24-month full dataset results of the Italian BICSTaR cohort
|
| 16.04 - 16.14 | ID 97 Evaluation of broad-spectrum piperazine-based compounds able to inhibit flavivirus and/or SARS-CoV-2 replication in a live virus assay
|
| 16.16 - 16.26 | ID 227 Long-term durability of dolutegravir + darunavir/cobicistat dual regimen in highly antiretroviral-experienced people living with HIV (DoDaco study)
|
| 16.28 - 16.35 | Conclusion
M.L. Cosmaro, E. Girardi |
Oral Communications
Clinical outcome of SARS-CoV-2 infection
Oral Communications
Oral Communications: Clinical outcome of SARS-CoV-2 infection
Chairs: R. Gagliardini, R. Gulminetti
| 16.40 - 16.45 | Introduction
R. Gagliardini, R. Gulminetti |
| 16.45 - 16.55 | ID 410 Multidisciplinary management with expertise in multigermic osteo-articular infections
|
| 16.57 - 17.07 | ID 183 Sexual assault is associated to loss to follow-up for non-occupational Post-Exposure Prophylaxis for HIV
|
| 17.09 - 17.19 | ID 338 Outreach programme in sex-on-premises venues: facilitating linkage to care and prevention services
|
| 17.21 - 17.31 | ID 48 Stigma and HIV. Perceptions in young people from Anlaids School
|
| 17.33 - 17.40 | Conclusion
R. Gagliardini, R. Gulminetti |
Special Session
Health and prevention in transgender people
Special Session
Health and prevention in transgender people
Studies carried out across a variety of different contexts have shown that transgender and gender diverse (TGD) people face significant barriers to accessing health care and health-determining resources, such as education, employment and housing. Harassment and discrimination contribute to high rates of stress and make transgender individuals significantly more likely to experience poor health outcomes (e.g., high risk for mental health morbidity, STI, cardiac disease, etc). Thus, it is urgently warranted to provide an effective and appropriate evidence-based prevention and care so as to ensure health equity for transgender people. In particular, TGD people are at high risk for HIV infection but prevention efforts targeting these people have been minimal. HIV pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV, however PrEP use among TGD people remains low. In this section, an overview of the main barriers that TGD people have to face accessing healtcare services will be given and possible future strategies will be discussed.
Chair: A. Palmitesta
| 11.10 - 11.25 | In-practice policies to promote an inclusive health care for transgender People
M. Pierdominici |
| 11.25 - 11.40 | Transgender health and communication strategies: the website Infotrans.it
M. Marconi |
| 11.40 - 11.55 | Sociosanitary conditions of transgender PWHIV: photography and possible inclusion tools
L. Brogonzoli |
| 11.55 - 12.10 | Barriers in the use HIV prophylaxis in transgender individuals
T. Bini |
Parallel Session
ARCA Scientific Board
Parallel Session
ARCA Scientific Board
La riunione del Board Scientifico tratterà lo stato attuale della coorte con un update sulle attività in corso e le prospettive progettuali, incluso il prossimo meeting ARCA Mentor School in programma a settembre a Siena.
Special Session
The Italian Fast-track Cities: strengths and weaknesses of a growing movement
Special Session
The Italian Fast-track Cities: strengths and weaknesses of a growing movement
Since December 2018, when Milan, the first Italian city, joined the global network of Fast-track Cities Initiative, the number of participating cities has steadily increased. This movement is one of the most important innovation in the national overview of territorial actions to reach the UNAIDS 95-95-95 goal by 2030. However, this growth is characterized by light and shadow. Some cities are blocked in their first declaration of intent or have difficulties in developing necessary collaboration between public institutions and social organisations in order to achieve tangible actions. Others cities are totally changing the face of fight against HIV in their own territories. A further difficulty, but which is also a possibility, concerns the sharing of good practices and the most effective actions between Italian Fast-track Cities.
Chairs: P. Meli, G. Orofino
| 15.35 - 15.45 | Activities in the last year of the Italian FTCs
I. Mercurio |
| 15.45 - 15.55 | The U=U campaign of the city of Turin
S.R. Patrucco |
| 15.55 - 16.05 | The first steps of the city of Ancona
L. Saracini |
| 16.05 - 16.15 | A project for the most vulnerable people in the city of Bergamo
D. Meli |
| 16.15 - 16.35 | Common projects and actions are possible? |
08:30 - 09:00 | Special Session
ICAR-CROI Awards 2023
09:00 - 10:30 | Session
Keynote Lectures
10:35 - 11:35 | Sponsored Symposium
Cabotegravir + Rilpivirine Long-Acting: a new dawn for PLHIV
11:40 - 12:40 | Symposium
The battle between the virus and the host: an ongoing dynamic process
12:45 - 13:45 | Symposium
Clinical COVID-19
14:00 - 15:00 | Symposium
Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection
15:05 - 16:05 | Symposium
Chemsex emergency - what happens in real life
16:10 - 16:30 | Special Session
ICAR 2023 Awards and Closing remarks
10:35 - 11:35 | Oral Communications
Bench studies of viral infections
11:40 - 12:40 | Oral Communications
Innovative tools for diagnosis and monitoring of viral infections
12:45 - 13:45 | Special Session
Drug pipeline: a glimpse of the future
14:00 - 15:00 | Oral Communications
Body and mind
15:05 - 16:05 | Oral Communications
Outcomes in treatment experienced PLWH
10:35 - 11:35 | Oral Communications
Liver, vessels and lipids
11:40 - 12:40 | Oral Communications
The experience of PrEP in Italy
12:45 - 13:45 | Oral Communications
Education and knowledge to reduce the burden of HIV and STIs
14:00 - 15:00 | Oral Communications
PACS: clinical outcome
15:05 - 16:05 | Oral Communications
Clinical approach to COVID in vulnerable populations
10:35 - 11:35 | Oral Communications
PACS: what to assess
11:40 - 12:40 | Oral Communications
Virological topics in SARS-CoV-2 infection
12:45 - 13:45 | Oral Communications
Real world evidence in different treatment setting
14:00 - 15:00 | Oral Communications
Viruses, resistance and drugs
15:05 - 16:05 | Oral Communications
Emerging issues in HIV-1 infection
14:00 - 15:00 | Oral Communications
Mpox and Immunopathogenic mechanisms
15:05 - 16:05 | Oral Communications
Novel clinical and epidemiological aspects of viral hepatitis
10:35 - 11:35 | Special Session
U=U: Impossibile Sbagliare
11:40 - 12:40 | Parallel Session
Meeting Prestigio Registry
12:50 - 14:00 | Parallel Session
HIV Outcomes in Europe
14:05 - 15:35
Investigator Meeting of EDOLAS study Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
Special Session
ICAR-CROI Awards 2023
Special Session
ICAR-CROI Awards 2023
This session is devoted to Young Italian Researchers - under 40 - who had an abstract accepted at CROI 2023. The following prizes will be announced and awarded: Two prizes for the best Clinical and Basic science Abstracts
Chairs: G. Angarano, F. Ceccherini Silberstein, G. d'Ettorre
· Prevalence, incidence, and risk factors for falls in older people with and without HIV S. Arsuffi |
|
· High RNAemia associates with skewed T-Cell response in PLWH hospitalized for COVID-19 M. Augello |
|
· Efficacy of 3TC+DTG vs 3-drug regimens in virologically-suppressed PLWH A. Borghetti |
|
· Mpox DNA clearance in semen over six months follow-up C. Candela |
|
· Increased burden of anal HPV-related potentially precancerous lesions in HIV+ women · Efficacy of late HPV vaccination in young HIV+ MSM E.N. Cavallari |
|
· Leukapheresis: a feasible tool to inform ati through HIV rereservoir study in children N. Cotugno |
|
· The impact of early outpatient treatments for COVID-19: a retrospective study M. Degli Antoni |
|
· mRNA vaccines induces a higher antibodies response in children with previous COVID-19 C. Di Chiara |
|
· Anemia as a predictor of poor clinical outcome in patients admitted for COVID-19 · Impact of the COVID-19 pandemic on Malaria services in Uganda: a time series analysis F. Di Gennaro |
|
· A joint analysis of two randomized controlled trials on enoxaparin for COVID-19 G. Dolci |
|
· Effects of chemoradiation on expanded proviral clones in an elite controller F. Dragoni |
|
· Mpox Virus in the pharynx of men having sex with men: a case series S. Limonta |
|
· Inflammasone but not IFN-I/III response is altered in children with long COVID L. Maddaloni |
|
· Screening approaches and clinical description of the anticholinergic burden in people with HIV M. Mazzitelli |
|
· Neutralizing and T cell response against mpox virus after MVA-BN vaccine · Comparison of subcutaneous versus intradermal route of administration of MVA vaccine · Humoral and cellular immune response after 3 months from Mpox Virus infection · SARS-CoV-2 Omicron viral load decrease after monoclonal antibodies or antivirals · Incidence and predictors of clinical progression in an early treated COVID-19 Cohort V. Mazzotta |
|
· Mortality linked to higher inflammation in perinatally-infected HIV+ kids E. Marrocchi |
|
· Immunogenicity of MVA-BN vaccination with hybrid administration route D. Moschese |
|
· Multifaceted premature aging in adolescent/young adult with perinatal-acquired HIV M.R. Petrara |
|
· Delayed positivization of non-lesion specimens among individuals with Mpox A.R. Raccagni |
|
· Adaptive immunity dysregulation is associated to the development of long COVID R. Rovito |
|
· Cap and metabolic profile worsening post-SRV in HCV-HIV people as a sign of steatosis A. Siribelli |
|
· DTG impact Zebrafish behaviour through dopaminergic pathways: rescue by folate S. Storti |
|
· The cerebrospinal fluid virome in virally suppressed people living with HIV · Neurocognitive impairment negatively affects viral control in Art-Treated PWH M. Trunfio |
|
· Neutralizing activity and T cell response after bivlent third booster dose in PLWH A. Vergori |
Session
Keynote Lectures
Session
Keynote Lectures
Chairs: G. Angarano, R. Cauda, A. Cossarizza
| 09.00 - 09.30 | Mpox 2022: the story of another pandemics
A. Antinori |
| 09.30 - 10.30 | COVID-19: virus vs immunocompromised host
M.S. Clerici, C.F. Perno |
Sponsored Symposium
Cabotegravir + Rilpivirine Long-Acting: a new dawn for PLHIV
Symposium
The battle between the virus and the host: an ongoing dynamic process
Symposium
The battle between the virus and the host: an ongoing dynamic process
The symposium is intended to address different topics concerning the delicate balance between protective and pathogenetic role of the immune system over viral infections. In particular, a comprehensive review of the most recent notions on early events (Type-I IFN-s) after HIV and SARS-CoV-2 infection will be provided. The role exerted by host immune factors and ART to contain HIV reservoir will be illustrated as well. The most novel technical approaches to gain exhaustive and more and more detailed information from biological specimens of infected patients will also be thoroughly reviewed during the symposium.
Chairs: C. Agrati, A. Cossarizza
| 11.40 - 11.55 | Type I Interferon in HIV and SARS-CoV-2 infection: following the mechanistic thread
C. Scagnolari |
| 11.55 - 12.10 | Drivers for virus reservoir containment: ART or host immune responses
A. De Maria |
| 12.10 - 12.25 | From bed to bench and return: what happens in between?
S. De Biasi |
| 12.25 - 12.40 | Discussion |
Symposium
Clinical COVID-19
Symposium
Clinical COVID-19
The symposium will present virological and clinical paradigms in the prophylaxis and treatment of SARS COV2 infection. In a multidisciplinary approach we will invite a psychiatrist to discuss immune-inflammatory pathways leading to psychopathology and neurocognitive impairment in LongCOVID with a focus on target for treatment. It will end with a round table comparing different models of care in the management of people with LongCOVID highlighting unmet clinical needs and research opportunities.
Chairs: G. Guaraldi, L. Sarmati
Moderator: G.C. Marchetti
Discussants: M. Andreoni, F. Benedetti, A.M. Cattelan, G. Guaraldi, G. Onder
| 12.45 - 13.00 | Paradigms of a prophylax and early treatment in COVID-19
M. Andreoni |
| 13.00 - 13.15 | Psychopathology and neurocognitive impairment in Long COVID: Immunopsychiatry of Long COVID
F. Benedetti |
| 13.15 - 13.45 | Round table |
| 13.15 - 13.25 | Introduction Lecture Challenges in Long-COVID care: Italian experiences and best practices
G. Onder |
| 13.25 - 13.45 | Discussion |
Symposium
Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection
Symposium
Clinical HIV first! Emerging and re-emerging clinical issues in HIV infection
HIV infection has taken on clinical connotations in the last two decades that are certainly different from what was observed at the beginning of the HIV epidemic. These changes have been induced by the universal use of antiretroviral therapy in our latitudes, although where therapy is not universally available, some clinical pictures may appear different and more similar to what was previously observed. The aim of this symposium is, on the one hand, to bring back the attention especially of young physicians to the classical clinical aspects of HIV infection by focusing on syndromic aspects in different situations of universal availability of ART, especially in terms of late presentation; on the other hand, it is intended to focus attention on particular clinical situations, toward which the availability of new treatments could change the natural history and prognosis of the diseases themselves, such as progressive multifocal leukoencephalopathy and HIV-related neoplasms.
Chairs: A. Bandera, G. Nunnari
| 14.00 - 14.20 | Syndromic approach to main opportunistic infections in HIV. Focus on limited resources - vs rich resources countries
C. Pinnetti |
| 14.20 - 14.40 | Progressive multifocal leucoencephalopathy. Update on diagnostics and therapeutic approaches
P.M. Cinque |
| 14.40 - 15.00 | New insights into innovative anti-cancer therapies and their application in HIV-related cancers
E. Vaccher |
Symposium
Chemsex emergency - what happens in real life
Symposium
Chemsex emergency - what happens in real life
Chemsex, or the use of recreational substances during sex, is a widespread practice within the MSM community. Numerous cohort studies on HIV-positive MSM or PrEP users show that the prevalence of the phenomenon is increasing and the substances used are constantly evolving. The chemsex emergency is often spoken of with emphasis on the health and addiction issues related to drug use, but also with a good deal of ignorance leading to stigmatisation of users. The symposium aims to shed light on this practice, providing information on the type of substances most commonly used, the contribution of peer practitioners in the field who, within community associations, offer support to chemsex users, and finally the fundamental role of PrEP in reducing the risk of HIV infection in contexts where other prevention tools would be of doubtful effectiveness.
Chairs: M.G.L. Cernuschi, D. Zagato
| 15.05 - 15.20 | Old and new psychotropic substances in chemsex practice
M. Lanza |
| 15.20 - 15.40 | Recreational Chemsex Vs problematic Chemsex
F. Leserri, M. Manfredini |
| 15.40 - 15.50 | Chemsex & PrEP
S. Nozza |
| 15.50 - 16.05 | Discussion |
Special Session
ICAR 2023 Awards and Closing remarks
Special Session
ICAR 2023 Awards and Closing remarks
ICAR and SIMIT support and reward the young excellences of Italian research with special prizes announced and awarded during this Session.
Chairs: F. Ceccherini Silberstein, M. Formisano, S. Lo Caputo, F. Maggiolo, C.M. Mastroianni, A. Saracino
| ICAR 2023 Scientific Committee Awards: Three prizes for the best Clinical, Basic science and Social sciences Abstracts
F. Maggiolo |
|
| SIMIT Special Awards: Five prizes for the best Oral Communications in: Clinical HIV, Clinical Hepatitis Virus, Clinical SARS-CoV-2, Virology and Immunopathogenesis, Epidemiology and Social sciences
C.M. Mastroianni |
|
| Closing remarks |
Oral Communications
Bench studies of viral infections
Oral Communications
Oral Communications: Bench studies of viral infections
Chairs: S. Parisi, C. Scagnolari
| 10.35 - 10.40 | Introduction
S. Parisi, C. Scagnolari |
| 10.40 - 10.50 | ID
|
| 10.52 - 11.02 | ID 271 Sexually transmitted infections in men-who-have-sex-with-men with HIV resistant to tenofovir/emtricitabine and/or cabotegravir
|
| 11.04 - 11.14 | ID 322 Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed people with HIV-1 switching to modern antiretroviral regimens
|
| 11.16 - 11.26 | ID 278 REPORTING A CLINICAL CASE OF LICHEN PLANUS/CUTANEUS LICHENOID DRUG ERUPTION ASSOCIATED WITH THE USE OF BIC/FTC/TAF
|
| 11.28 - 11.35 | Conclusion
S. Parisi, C. Scagnolari |
Oral Communications
Innovative tools for diagnosis and monitoring of viral infections
Oral Communications
Oral Communications: Innovative tools for diagnosis and monitoring of viral infections
Chairs: C. Alteri, C. Torti
| 11.40 - 11.45 | Introduction
C. Alteri, C. Torti |
| 11.45 - 11.55 | ID 353 Modena and Emilia Romagna HIV Surveillance: the application of ECDC HIV Modelling Tool
|
| 11.57 - 12.07 | ID 281 Neutralizing antibodies titers against ten viral Spike protein variants of SARS-CoV-2 in the serum of patients receiving dialysis before and 30 days after the XBB1.5 updated mRNA vaccination
|
| 12.09 - 12.19 | ID 254 Inflammatory milieu and specific T cells response after three months and one year from SARS-CoV-2 infection
|
| 12.21 - 12.31 | ID 145 The importance of contact tracing in STIs: a lesson learned from scabies outbreaks
|
| 12.33 - 12.40 | Conclusion
C. Alteri, C. Torti |
Special Session
Drug pipeline: a glimpse of the future
Special Session
Drug pipeline: a glimpse of the future
An open discussion between researchers and R&D representatives of pharmaceutical companies that aims to outline and shape the future of antiviral drug and vaccines development in the next decade
Chairs: C. Mussini, C.F. Perno, S. Vella
| 12.45 - 12.50 | Introduction |
| 12.50 - 12.55 | Emiliano Bissio, Global Director Medical Affairs (HIV) at MSD |
| 12.55 - 13.00 | Gian Marco Prandi, Associate Director Medical Affairs Vaccines at MSD Italy |
| 13.00 - 13.10 | Martin Gartland, Vice President, Early Development Lead, Pipeline at ViiV Healthcare |
| 13.10 - 13.20 | Felipe Rogatto, Executive Director of Global HIV Medical Affairs - Franchise & Strategic Implementation at Gilead Sciences |
| 13.20 - 13.25 | Foteini Gkalapi, Medical Lead Vaccines Europe - Belgium at GSK |
| 13.25 - 13.30 | Shayon Salehi, Medical Director, Global Medical Affairs at GSK |
| 13.30 - 13.45 | Q&A and Discussion |
Oral Communications
Body and mind
Oral Communications
Oral Communications: Body and mind
Chairs: T. Bini, G. Rizzardini
| 14.00 - 14.05 | Introduction
T. Bini, G. Rizzardini |
| 14.05 - 14.15 | ID 350 UniversiTest: peer to peer approaching. Informing and Testing
|
| 14.17 - 14.27 | ID 467 Chemsex addiction in one heterosexual man - a cure through psychodynamic psychotherapy
|
| 14.29 - 14.39 | ID 103 Idiosyncratic drug liver injury during long-acting HIV treatment: A Case Report
|
| 14.41 - 14.51 | ID
|
| 14.53 - 15.00 | Conclusion
T. Bini, G. Rizzardini |
Oral Communications
Outcomes in treatment experienced PLWH
Oral Communications
Oral Communications: Outcomes in treatment experienced PLWH
Chairs: A.M. Cattelan, A. Moznich
| 15.05 - 15.10 | Introduction
A.M. Cattelan, A. Moznich |
| 15.10 - 15.20 | ID 251 Impact of PrEP cost on prophylaxis initiation in an Italian centre
|
| 15.22 - 15.32 | ID
|
| 15.34 - 15.44 | ID 230 HBs isoforms as innovative biomarkers in predicting virological response in chronic hepatitis delta patients treated with bulevirtide monotherapy
|
| 15.46 - 15.56 | ID 212 Increasing Gonorrhea and Chlamydia infections observed in MSM in the early 2024
|
| 15.58 - 16.05 | Conclusion
A.M. Cattelan, A. Moznich |
Oral Communications
Liver, vessels and lipids
Oral Communications
Oral Communications: Liver, vessels and lipids
Chairs: P. Blanc, A. Cingolani
| 10.35 - 10.40 | Introduction
P. Blanc, A. Cingolani |
| 10.40 - 10.50 | ID 149 HIV testing in Italian community and outreach sites: COBATEST network, 2020-2023
|
| 10.52 - 11.02 | ID 27 Lipids, weight gain and Body Mass Index in ARV experienced PLWH treated with Doravirine-based treatments: a comparison between dual or triple regimens vs Bictegravir based triple regimen.
|
| 11.04 - 11.14 | ID
|
| 11.16 - 11.26 | ID
|
| 11.28 - 11.35 | Conclusion
P. Blanc, A. Cingolani |
Oral Communications
The experience of PrEP in Italy
Oral Communications
Oral Communications: The experience of PrEP in Italy
Chairs: E. Focà, F.P. Maraglino
| 11.40 - 11.45 | Introduction
E. Focà, F.P. Maraglino |
| 11.45 - 11.55 | ID 72 Experience of a community-based chemsex service: analysis of requests for help during the MDPV outbreak
|
| 11.57 - 12.07 | ID 98 Assessment of comprehensive sexuality education: a framework of indicators to evaluate interventions in Italian secondary schools
|
| 12.09 - 12.19 | ID 235 Safety and effectiveness of switching PWH with occult HBV infection to tenofovir-sparing regimens
|
| 12.21 - 12.31 | ID 449 Evaluation of injectable long acting cabotegravir as response to oral PrEP-related medical issues
|
| 12.33 - 12.40 | Conclusion
E. Focà, F.P. Maraglino |
Oral Communications
Education and knowledge to reduce the burden of HIV and STIs
Oral Communications
Oral Communications: Education and knowledge to reduce the burden of HIV and STIs
Chairs: N. Frattini, R. Galipò
| 12.45 - 12.50 | Introduction
N. Frattini, R. Galipò |
| 12.50 - 13.00 | ID 418 Investigating seroprevalence of IgG against Dengue virus (DENV) in a cohort of people with HIV (PLWH) in a non-endemic country after an autochthonous outbreak: are we ready for next season?
|
| 13.02 - 13.12 | ID 349 Aspergillus spp infection in immunocompromised and non-neutropenic patients in Infection Intensive Care: a retrospective observational study
|
| 13.14 - 13.24 | ID 190 ACTIVE CLOSE CONTACT INVESTIGATION OF TUBERCULOSIS THROUGH COMPUTER-AIDED DETECTION AND STOOL XPERT MTB/RIF AMONG PEOPLE LIVING IN OROMIA REGION, ETHIOPIA: A PRELIMINARY RESULTS
|
| 13.26 - 13.36 | ID 99 A systematic and evidence-based approach in vaccination of people living with HIV: the Notebook of Clinical Vaccinology
|
| 13.38 - 13.45 | Conclusion
N. Frattini, R. Galipò |
Oral Communications
PACS: clinical outcome
Oral Communications
Oral Communications: PACS: clinical outcome
Chairs: G. Cenderello, D. Ripamonti
| 14.00 - 14.05 | Introduction
G. Cenderello, D. Ripamonti |
| 14.05 - 14.15 | ID 234 Cumulative risk of discontinuation of modern first-line ART by reason for stopping and type of ART initiated: findings from the ICONA cohort
|
| 14.17 - 14.27 | ID 305 Durability of doravirine/lamivudine/tenofovir disoproxil fumarate in a cohort of treatment-experienced people with HIV: a retrospective observational study.
|
| 14.29 - 14.39 | ID 351 African women living with HIV in Modena: far from fulfilling the gap
|
| 14.41 - 14.51 | ID 236 First case of hepatitis B virus (HBV) reactivation in a patient with breast cancer receiving CDK4/6 inhibitor drugs
|
| 14.53 - 15.00 | Conclusion
G. Cenderello, D. Ripamonti |
Oral Communications
Clinical approach to COVID in vulnerable populations
Oral Communications
Oral Communications: Clinical approach to COVID in vulnerable populations
Chairs: F. Di Gennaro, C. Gervasoni
| 15.05 - 15.10 | Introduction
F. Di Gennaro, C. Gervasoni |
| 15.10 - 15.20 | ID
|
| 15.22 - 15.32 | ID 473 A machine learning tool to operationalize Intrinsic Capacity in predicting recovery from post-acute sequelae COVID-19
|
| 15.34 - 15.44 | ID 79 Vaccine uptake pre and post COVID-19 pandemic among PLWH
|
| 15.46 - 15.56 | ID
|
| 15.58 - 16.05 | Conclusion
F. Di Gennaro, C. Gervasoni |
Oral Communications
PACS: what to assess
Oral Communications
Oral Communications: PACS: what to assess
Chairs: G. Guaraldi, L. Sarmati
| 10.35 - 10.40 | Introduction
G. Guaraldi, L. Sarmati |
| 10.40 - 10.50 | ID
|
| 10.52 - 11.02 | ID 299 Efficacy, safety and discontinuation of rilpivirine and cabotegravir in HIV-1 virologically suppressed adults: a multicenter observational study in Tuscany (LAHIV study)
|
| 11.04 - 11.14 | ID 336 Respiratory syncytial virus viral load and co-infection in a very large cohort of pediatric patients, which role in the disease severity?
|
| 11.16 - 11.26 | ID
|
| 11.28 - 11.35 | Conclusion
G. Guaraldi, L. Sarmati |
Oral Communications
Virological topics in SARS-CoV-2 infection
Oral Communications
Oral Communications: Virological topics in SARS-CoV-2 infection
Chairs: S. Carbonara, I. Vicenti
| 11.40 - 11.45 | Introduction
S. Carbonara, I. Vicenti |
| 11.45 - 11.55 | ID 127 Dyslipidemia and real-life prescription of statins among People Living With HIV enrolled in Archi Prevaleat cohort.
|
| 11.57 - 12.07 | ID
|
| 12.09 - 12.19 | ID 200 HIV-DNA quantification as prediction of GRT success in HIV-DNA NGS
|
| 12.21 - 12.31 | ID 229 Correlation among bone, endothelial and hepatic damage in PLWH
|
| 12.33 - 12.40 | Conclusion
S. Carbonara, I. Vicenti |
Oral Communications
Real world evidence in different treatment setting
Oral Communications
Oral Communications: Real world evidence in different treatment setting
Chairs: A. Di Biagio, M. Poliseno
| 12.45 - 12.50 | Introduction
A. Di Biagio, M. Poliseno |
| 12.50 - 13.00 | ID 153 Central Nervous System and Neuropsychiatric adverse events in Women Living with HIV treated with INSTI-based regimens
|
| 13.02 - 13.12 | ID 151 An alliance in communication: LILA training for journalists
|
| 13.14 - 13.24 | ID
|
| 13.26 - 13.36 | ID 455 Periaortic BCGite in HIV
|
| 13.38 - 13.45 | Conclusion
A. Di Biagio, M. Poliseno |
Oral Communications
Viruses, resistance and drugs
Oral Communications
Oral Communications: Viruses, resistance and drugs
Chairs: B. Bruzzone, F. Saladini
| 14.00 - 14.05 | Introduction
B. Bruzzone, F. Saladini |
| 14.05 - 14.15 | ID 158 Clinical and Immunovirological Features of Potential Post Treatment HIV Controllers
|
| 14.17 - 14.27 | ID 297 Neutral Metabolic Impact of Long-Acting CAB+RPV in PLWH: A Tuscan Multicenter Observational Study (LAHIV)
|
| 14.29 - 14.39 | ID 301 Problematic chemsex: a multidisciplinary approach
|
| 14.41 - 14.51 | ID
|
| 14.53 - 15.00 | Conclusion
B. Bruzzone, F. Saladini |
Oral Communications
Emerging issues in HIV-1 infection
Oral Communications
Oral Communications: Emerging issues in HIV-1 infection
Chairs: B.M. Celesia, G. Giupponi
| 15.05 - 15.10 | Introduction
B.M. Celesia, G. Giupponi |
| 15.10 - 15.20 | ID 414 Exploring cardiovascular risk in people with HIV: the critical role of intima-media thickness
|
| 15.22 - 15.32 | ID 383 Exploring the Use of Darunavir Boosted plus Dolutegravir in Highly Treatment-Experienced HIV Population: A Retrospective Cohort Study
|
| 15.34 - 15.44 | ID 26 The prevalence of HDV in a cohort of HbsAg positive patients referred to an Infectious Diseases Clinic
|
| 15.46 - 15.56 | ID 337 Hepatitis delta testing in adults with chronic hepatitis B virus infection attending for outpatient care: Who are those unscreened?
|
| 15.58 - 16.05 | Conclusion
B.M. Celesia, G. Giupponi |
Oral Communications
Mpox and Immunopathogenic mechanisms
Oral Communications
Oral Communications: Mpox and Immunopathogenic mechanisms
Chairs: F. Maggi, V. Mazzotta
| 14.00 - 14.05 | Introduction
F. Maggi, V. Mazzotta |
| 14.05 - 14.15 | ID 282 Neutralizing antibody response to the highly divergent BA.2.86 SARS-CoV-2 lineages in vaccinated health care workers with or without subsequent infection
|
| 14.17 - 14.27 | ID 480 Sex disparity in COVID infection: a retrospective study using serum electrophoretic analysis (SPE) in men and women infected by COVID-19
|
| 14.29 - 14.39 | ID 87 “TelePrEP” – A pilot program for the delivery of remote PrEP services
|
| 14.41 - 14.51 | ID 279 HIV acquisition at birth does not drive T-cell dysfunction in Heavily Treatment Experienced (HTE): data from the Prestigio Registry
|
| 14.53 - 15.00 | Conclusion
F. Maggi, V. Mazzotta |
Oral Communications
Novel clinical and epidemiological aspects of viral hepatitis
Oral Communications
Oral Communications: Novel clinical and epidemiological aspects of viral hepatitis
Chairs: G. Lapadula, T.A. Santantonio
| 15.05 - 15.10 | Introduction
G. Lapadula, T.A. Santantonio |
| 15.10 - 15.20 | ID 269 Clinical outcome of switching to a dual drug regimen (2DR) vs. switching or remaining on a triple (3DR) regimen in the setting of a viral load ≤50 copies/mL
|
| 15.22 - 15.32 | ID 446 HPV test in anal specimens: a preliminary evaluation on sampling quality
|
| 15.34 - 15.44 | ID
|
| 15.46 - 15.56 | ID
|
| 15.58 - 16.05 | Conclusion
G. Lapadula, T.A. Santantonio |
Special Session
U=U: Impossibile Sbagliare
Special Session
U=U: Impossibile Sbagliare
U=U represents the most revolutionary principle and the most effective tool to break down stigma and discrimination against people living with HIV (PLWH) and to improve acceptance of infection and break down self-stigma in PLWH themselves. For this, ICAR's Community Associations constructed a "prospective study to evaluate the impact of a U=U information campaign in two target populations": PLWH and the general population. In this first phase, the construction of the study will be explained and the communication campaign "U=U: No brainer" will be presented.
Chairs: M. Farinella, F. Schloesser
| 10.35 - 11.35 | Presentation of the communication campaign and methodologies of the impact assessment study
D. Calzavara, N. Frattini |
Parallel Session
Meeting Prestigio Registry
Parallel Session
Meeting Prestigio Registry
The PRESTIGIO REGISTRY opens its doors to the ICAR community. The meeting will be an opportunity to share the updated profile of the Registry, as well as to present the achievements, ongoing initiatives and research projects to all participating centers.
Chair: A. Castagna
| 11.40 - 11.55 | PRESTIGIO Registry Update
A. Castagna |
| 11.55 - 12.10 | Publications
L. Galli |
| 12.10 - 12.25 | Current initiatives and research projects
V. Spagnuolo |
| 12.25 - 12.40 | Questions and Answers
E. Carini, R. Lolatto |
Parallel Session
HIV Outcomes in Europe
Parallel Session
HIV Outcomes in Europe
HIV Outcomes is a European initiative born in 2016, thanks to the support of the members of the European Parliament, bringing together patient organisations, clinicians, academics, public institutions and the private sector to think about a new way of addressing the needs of HIV-positive people, to guarantee that they can live longer, in good health and fully participate in society. HIV Outcomes aims to sensitise policy makers and to implement actions that lead to a patient-centric health system that also includes a change in the clinical approach. Improving the quality of life of people living with HIV means improving the sustainability of European health systems through the sharing of best practices and innovative approaches to care. In 2017 HIV Outcomes presented its 5 Recommendations on the health, well-being and long-term care of people living with HIV to the European Parliament. In 2020, to bring the right attention on HIV of Italian political decision-makers, being at the same time members of the European Parliament, and by healthcare professionals, HIV Outcomes Italia was then created. The ultimate aim is to disseminate the recommendations and vision of HIV Outcomes Europe at national level. In 2022, the Policy Asks, developed together with national initiatives Enhancing long-term health and well-being among people living with HIV were presented to the European Parliament.
| 12.50 - 13.00 | Presentation of the initiative
A. d'Arminio Monforte |
| 13.00 - 13.10 | Policy Asks
M. Cascio |
| 13.10 - 13.15 | The involvement of the Institutions
S. Milano |
| 13.15 - 13.20 | The work done, Delphi on Recommendations and initial Institutions engagement
A. d'Arminio Monforte |
| 13.20 - 13.25 | Abstract on Surveys on Residential care Homes and Hospitals
L. Brogonzoli |
| 13.25 - 13.40 | The way forward on Ageing
M. Cascio, A. d'Arminio Monforte |
| 13.40 - 14.00 | Questions and Answers |
Investigator Meeting of EDOLAS study Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
Investigator Meeting of EDOLAS study Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
| 14.05 - 14.10 | Welcome
A. Antinori, F. Maggiolo |
| 14.10 - 14.15 | Introduction
A. Antinori, F. Maggiolo |
| 14.15 - 14.30 | Protocol and enrolments
R. Gagliardini |
| 14.30 - 14.50 | Discussion |
| 14.50 - 15.30 | Meeting with investigators of the Edolas substudies |
| 15.30 - 15.35 | Conclusions
A. Antinori |
Promosso da
